Post «Coda Biotherapeutics is developing a cure for pain» in blog Прогноз погоды

People

John Smith

John Smith, 48

Joined: 28 January 2014

Interests: No data

Jonnathan Coleman

Jonnathan Coleman, 32

Joined: 18 June 2014

About myself: You may say I'm a dreamer

Interests: Snowboarding, Cycling, Beer

Andrey II

Andrey II, 41

Joined: 08 January 2014

Interests: No data

David

David

Joined: 05 August 2014

Interests: No data

David Markham

David Markham, 65

Joined: 13 November 2014

Interests: No data

Michelle Li

Michelle Li, 41

Joined: 13 August 2014

Interests: No data

Max Almenas

Max Almenas, 53

Joined: 10 August 2014

Interests: No data

29Jan

29Jan, 32

Joined: 29 January 2014

Interests: No data

s82 s82

s82 s82, 26

Joined: 16 April 2014

Interests: No data

Wicca

Wicca, 37

Joined: 18 June 2014

Interests: No data

Phebe Paul

Phebe Paul, 27

Joined: 08 September 2014

Interests: No data

Артем Ступаков

Артем Ступаков, 93

Joined: 29 January 2014

About myself: Радуюсь жизни!

Interests: No data

sergei jkovlev

sergei jkovlev, 59

Joined: 03 November 2019

Interests: музыка, кино, автомобили

Алексей Гено

Алексей Гено, 8

Joined: 25 June 2015

About myself: Хай

Interests: Интерес1daasdfasf, http://apple.com

technetonlines

technetonlines

Joined: 24 January 2019

Interests: No data



Coda Biotherapeutics is developing a cure for pain

17:29 | 5 November expand

Coda Biotherapeutics is developing a cure for pain

If the researchers, executives and investors behind Coda Biotherapeutics have their way, one day soon there really could be a cure for pain.

Co-founded by researchers Joseph Glorioso, from the University of Pittsburgh’s microbiology and molecular genetics department; and Dr. Nicholas Boulis, the founder of Emory’s Gene and Cell Therapy for Neurorestoration Laboratory; Coda uses gene therapies to treat neurological diseases starting with severe pain and epilepsy.

America is a country in pain. There are over 19 million Americans who live with chronic neuropathic pain, according to Coda’s own statistics. And over the past twenty years the doctors treating those Americans and the drug companies developing therapies for them have managed to turn their treatment into a new epidemic — opioid addiction.

In 2017, 47,600 Americans died from opioid-involved overdoses, according to the Centers for Disease Control. Of those deaths, about 60% involved synthetic opioids.

“The incentives were there for people to prescribe more and more, particularly when they had already been convinced it was the right thing to do — the compassionate thing to do,” Keith Humphreys, a psychiatrist at Stanford University and a former White House drug-policy adviser, told the journal Nature.

As the pain epidemic and attendant opioid crisis began to skyrocket several companies have been racing to find alternatives to the drug treatments that were now killing Americans by the thousands. Other approaches like electrical nerve stimulation can carry risks, and invasive surgeries are an unappealing last resort, according to Coda’s chief executive.

Coda’s experimental treatment is based on a science called chemogenetics, which uses a harmless virus to create new receptors in the sensory neurons that provide signals to the brain about physical stimuli. Those receptors can be unlocked by small molecule drugs, which would instruct the sensory neurons to stop firing, thereby cutting off the signals of pain to the brain.

Coda Biotherapeutics is developing a cure for pain

Coda’s virus on a neural cell (Image courtesy of Coda Biotherapeutics)

The idea behind chemogenetics is to engineer a receptor that when you put it in with a… gene therapy… it does nothing. We’ve engineered it so that it is no longer responsive,” says Michael Narachi, the president and chief executive officer at Coda. “Most of these receptors are naturally opened or closed by acetylcholine… We’ve engineered these receptors so that  they’re no longer responsive to acetylcholine, but they are responsive to a man-made drug.”

The company then draws from a portfolio of receptor small-molecule drug pairs that were developed and tested for their pharmacological and toxicological effects, but discarded because of a lack of efficacy, to create new therapies with receptors tailored to respond to those drugs.

“What we’ve done is flipped the whole paradigm on its head. We’re making the lock that can work with these keys,” says Narachi. 

So far, the company has raised $34 million as investors including Versant Ventures, MPM Capital and Astellas Venture Management have doubled down on their initial $19 million commitment to the new drug developer. 

“Since coming out of stealth mode last September, the CODA team has made tremendous progress in developing its gene therapy program that is tunable, durable and highly selective, which allows for better efficacy and safety with fewer off-target effects,” said Tom Woiwode, Ph.D., managing director at Versant Ventures and CODA Chairman, in a statement. “CODA’s platform holds great promise to significantly transform how we treat challenging conditions and disorders for which new therapeutic options are greatly needed.” 

Pain isn’t the only condition that Coda hopes to treat. The company is also working on therapies that can reduce the severity of epilepsy for the nearly 3.4 million people in the U.S. who have the condition. While the company can’t treat all kinds of epilepsy, Coda says that it could address focal epilepsy, which represents 60% of all manifestations of the condition, and is linked to a specific region of the brain.

By engineering neurotransmitter receptors that are activated by medicines that can be taken orally, Coda thinks it can control the activity of neurons responsible for both chronic pain and focal epilepsy.

The next step for the company — and part of the use of proceeds from its new $15 million cash infusion — will . be to proceed with early animal trials. These clinical trials will be followed by human trials.

“This is a research platform,” says Narachi. “We have this portfolio of engineered receptors and we’re testing them in cells. The next step is to go into human clinical trials.”

Coda Biotherapeutics is developing a cure for pain Coda Biotherapeutics is developing a cure for pain Coda Biotherapeutics is developing a cure for pain Coda Biotherapeutics is developing a cure for pain Coda Biotherapeutics is developing a cure for pain Coda Biotherapeutics is developing a cure for pain
Coda Biotherapeutics is developing a cure for pain

 


Read more→

Posted on 05.11.2019 17:29

Comments

To show the previous comments (%s from %s)
Show new comments

Last comments

Walmart retreats from its UK Asda business to hone its focus on competing with Amazon
Peter Short
Good luck
Peter Short

Evolve Foundation launches a $100 million fund to find startups working to relieve human suffering
Peter Short
Money will give hope
Peter Short

Boeing will build DARPA’s XS-1 experimental spaceplane
Peter Short
Great
Peter Short

Is a “robot tax” really an “innovation penalty”?
Peter Short
It need to be taxed also any organic substance ie food than is used as a calorie transfer needs tax…
Peter Short

Twitter Is Testing A Dedicated GIF Button On Mobile
Peter Short
Sounds great Facebook got a button a few years ago
Then it disappeared Twitter needs a bottom maybe…
Peter Short

Apple’s Next iPhone Rumored To Debut On September 9th
Peter Short
Looks like a nice cycle of a round year;)
Peter Short

AncestryDNA And Google’s Calico Team Up To Study Genetic Longevity
Peter Short
I'm still fascinated by DNA though I favour pure chemistry what could be
Offered is for future gen…
Peter Short

U.K. Push For Better Broadband For Startups
Verg Matthews
There has to an email option icon to send to the clowns in MTNL ... the govt of India's service pro…
Verg Matthews

CrunchWeek: Apple Makes Music, Oculus Aims For Mainstream, Twitter CEO Shakeup
Peter Short
Noted Google maybe grooming Twitter as a partner in Social Media but with whistle blowing coming to…
Peter Short

CrunchWeek: Apple Makes Music, Oculus Aims For Mainstream, Twitter CEO Shakeup
Peter Short
Noted Google maybe grooming Twitter as a partner in Social Media but with whistle blowing coming to…
Peter Short


Site search